FMP
Oct 21, 2024 5:08 PM - Alex Lavoie
Image credit: Google Images
On October 21, 2024, Cantor Fitzgerald maintained its "Overweight" rating for CVRx, Inc. (NASDAQ: CVRX), a company specializing in medical devices. The stock was held at a price of $10.55. CVRx focuses on innovative therapies for heart failure, with its flagship product being Barostim, a baroreflex activation therapy.
Recently, CVRx announced that the American Medical Association (AMA) approved new CPT Category I codes for Barostim. This approval is significant as it acknowledges the therapy's growing use and positive clinical outcomes. The new codes, effective January 1, 2026, will likely improve reimbursement processes for healthcare providers, broadening patient access to Barostim.
The stock price of CVRX has seen a notable increase, currently trading at $10.91, up by 14.96% or $1.42. This rise reflects investor optimism following the AMA's approval. The stock has fluctuated today between $9.65 and $11.03, indicating active trading interest.
CVRx's market capitalization is approximately $237.68 million, with a trading volume of 583,553 shares. Over the past year, the stock has experienced a high of $33.14 and a low of $6.40. This volatility highlights the market's response to the company's developments and potential growth prospects.
Oct 21, 2024 1:05 PM - Alex Lavoie
Steel Dynamics Inc. (NASDAQ:STLD) is a prominent player in the steel industry, known for its innovative steel production and recycling operations. The company competes with other major steel producers like Nucor Corporation and ArcelorMittal. On October 21, 2024, Glenn Pushis, Senior Vice President ...
Oct 21, 2024 1:50 PM - Davit Kirakosyan
Lumen Technologies (NYSE:LUMN) saw its shares surge by more than 15% intra-day today following the announcement of a strategic collaboration with Meta Platforms (NASDAQ:META) designed to significantly expand network capacity to support Meta’s rapidly growing artificial intelligence (AI) infrastructu...